Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML

Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1 and 2) have opened new avenues of treatment. We present a 60-year-old woman with refractor...

Descripción completa

Detalles Bibliográficos
Autores principales: Jasra, Sakshi, Kazemi, Mohammed, Shah, Nishi, Chen, Jiahao, Fehn, Karen, Wang, Yanhua, Mantzaris, Ioannis, Kornblum, Noah, Sica, Alejandro, Bachier, LizaMarie, Goldfinger, Mendel, Gritsman, Kira, Braunschweig, Ira, Steidl, Ulrich, Shastri, Aditi, Verma, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784272/
https://www.ncbi.nlm.nih.gov/pubmed/33397455
http://dx.doi.org/10.1186/s40164-020-00186-y
_version_ 1783632274960416768
author Jasra, Sakshi
Kazemi, Mohammed
Shah, Nishi
Chen, Jiahao
Fehn, Karen
Wang, Yanhua
Mantzaris, Ioannis
Kornblum, Noah
Sica, Alejandro
Bachier, LizaMarie
Goldfinger, Mendel
Gritsman, Kira
Braunschweig, Ira
Steidl, Ulrich
Shastri, Aditi
Verma, Amit
author_facet Jasra, Sakshi
Kazemi, Mohammed
Shah, Nishi
Chen, Jiahao
Fehn, Karen
Wang, Yanhua
Mantzaris, Ioannis
Kornblum, Noah
Sica, Alejandro
Bachier, LizaMarie
Goldfinger, Mendel
Gritsman, Kira
Braunschweig, Ira
Steidl, Ulrich
Shastri, Aditi
Verma, Amit
author_sort Jasra, Sakshi
collection PubMed
description Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1 and 2) have opened new avenues of treatment. We present a 60-year-old woman with refractory AML, achieving complete response to the combination therapy of hypomethylating agent, Azacytidine with the IDH2 inhibitor, Enasidenib, and BCL2 inhibitor, Venetoclax. To our knowledge, this is the first case report of a patient with IDH2 mutated refractory AML achieving complete response to combination therapy with azacytidine, enasidenib and venetoclax.
format Online
Article
Text
id pubmed-7784272
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77842722021-01-14 Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML Jasra, Sakshi Kazemi, Mohammed Shah, Nishi Chen, Jiahao Fehn, Karen Wang, Yanhua Mantzaris, Ioannis Kornblum, Noah Sica, Alejandro Bachier, LizaMarie Goldfinger, Mendel Gritsman, Kira Braunschweig, Ira Steidl, Ulrich Shastri, Aditi Verma, Amit Exp Hematol Oncol Letter to the Editor Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1 and 2) have opened new avenues of treatment. We present a 60-year-old woman with refractory AML, achieving complete response to the combination therapy of hypomethylating agent, Azacytidine with the IDH2 inhibitor, Enasidenib, and BCL2 inhibitor, Venetoclax. To our knowledge, this is the first case report of a patient with IDH2 mutated refractory AML achieving complete response to combination therapy with azacytidine, enasidenib and venetoclax. BioMed Central 2021-01-04 /pmc/articles/PMC7784272/ /pubmed/33397455 http://dx.doi.org/10.1186/s40164-020-00186-y Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Letter to the Editor
Jasra, Sakshi
Kazemi, Mohammed
Shah, Nishi
Chen, Jiahao
Fehn, Karen
Wang, Yanhua
Mantzaris, Ioannis
Kornblum, Noah
Sica, Alejandro
Bachier, LizaMarie
Goldfinger, Mendel
Gritsman, Kira
Braunschweig, Ira
Steidl, Ulrich
Shastri, Aditi
Verma, Amit
Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
title Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
title_full Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
title_fullStr Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
title_full_unstemmed Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
title_short Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
title_sort case report of combination therapy with azacytidine, enasidenib and venetoclax in primary refractory aml
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784272/
https://www.ncbi.nlm.nih.gov/pubmed/33397455
http://dx.doi.org/10.1186/s40164-020-00186-y
work_keys_str_mv AT jasrasakshi casereportofcombinationtherapywithazacytidineenasidenibandvenetoclaxinprimaryrefractoryaml
AT kazemimohammed casereportofcombinationtherapywithazacytidineenasidenibandvenetoclaxinprimaryrefractoryaml
AT shahnishi casereportofcombinationtherapywithazacytidineenasidenibandvenetoclaxinprimaryrefractoryaml
AT chenjiahao casereportofcombinationtherapywithazacytidineenasidenibandvenetoclaxinprimaryrefractoryaml
AT fehnkaren casereportofcombinationtherapywithazacytidineenasidenibandvenetoclaxinprimaryrefractoryaml
AT wangyanhua casereportofcombinationtherapywithazacytidineenasidenibandvenetoclaxinprimaryrefractoryaml
AT mantzarisioannis casereportofcombinationtherapywithazacytidineenasidenibandvenetoclaxinprimaryrefractoryaml
AT kornblumnoah casereportofcombinationtherapywithazacytidineenasidenibandvenetoclaxinprimaryrefractoryaml
AT sicaalejandro casereportofcombinationtherapywithazacytidineenasidenibandvenetoclaxinprimaryrefractoryaml
AT bachierlizamarie casereportofcombinationtherapywithazacytidineenasidenibandvenetoclaxinprimaryrefractoryaml
AT goldfingermendel casereportofcombinationtherapywithazacytidineenasidenibandvenetoclaxinprimaryrefractoryaml
AT gritsmankira casereportofcombinationtherapywithazacytidineenasidenibandvenetoclaxinprimaryrefractoryaml
AT braunschweigira casereportofcombinationtherapywithazacytidineenasidenibandvenetoclaxinprimaryrefractoryaml
AT steidlulrich casereportofcombinationtherapywithazacytidineenasidenibandvenetoclaxinprimaryrefractoryaml
AT shastriaditi casereportofcombinationtherapywithazacytidineenasidenibandvenetoclaxinprimaryrefractoryaml
AT vermaamit casereportofcombinationtherapywithazacytidineenasidenibandvenetoclaxinprimaryrefractoryaml

Ejemplares similares